HC Wainwright & Co. Reiterates Buy on eFFECTOR Therapeutics, Maintains $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and maintained a $24 price target.
March 28, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on eFFECTOR Therapeutics with a $24 price target.
The reiteration of a Buy rating and maintenance of a $24 price target by a reputable analyst like Robert Burns could instill confidence among investors and potentially drive up the stock price of eFFECTOR Therapeutics in the short term. The specific mention of the company and the reaffirmation of a high price target suggest a strong positive outlook on the company's performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100